The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes

Bortezomib (BTZ) is a first-in-class proteasome inhibitor approved for the therapy of multiple myeloma that also displays unique regulatory activities on immune cells. The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan metabolizing enzyme exerting potent immunoregulatory effects when ex...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Mondanelli, Giada, Albini, Elisa, Pallotta, Maria T., Volpi, Claudia, Chatenoud, Lucienne, Kuhn, Chantal, Fallarino, Francesca, Matino, Davide, Belladonna, Maria L., Bianchi, Roberta, Vacca, Carmine, Bicciato, Silvio, Boon, Louis, Ricci, Giovanni, Grohmann, Ursula, Puccetti, Paolo, Orabona, Ciriana
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2017
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5390013/
https://ncbi.nlm.nih.gov/pubmed/28450863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.00428
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados